Our findings suggest that selective inhibition of CDK6 expression, rather than the use of CDK4/6 dual inhibitors such as palbociclib, during RA treatment, may preclude the adverse effects of myelosuppression and offer potential therapeutic benefits in RA. This evidence concerns the gene CDK6 and rheumatoid arthritis.